Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

    Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

    Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

    We pioneer breakthroughs in healthcare. For everyone. Everywhere. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

    1. Home

    2. Perspectives

    3. High-Sensitivity Troponin I Assays: A Breakthrough...
    Cardiology

    High-Sensitivity Troponin I Assays: A Breakthrough in AMI Diagnosis

    5min
    Diana Smith
    Published on August 28, 2017
    Cvd disease has been the leading cause of death worldwide for the last 15 years. Thanks to high-sensitivity troponin I assays, new possibilities have emerged for quicker, more accurate diagnoses of myocardial infarction.

    Peter Kavsak, PhD, Associate Professor of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario, Canada

    Chest pain is a common symptom of specific cvd diseases. The use of high-sensitivity troponin assays has the potential to change how patients with chest pain are triaged in the emergency department.

    Taking aim at a global killer

    Low levels of high-sensitivity troponin can rule out acute myocardial infarction with a single draw eliminating the need for serial measurements.

    Faster rule-in/rule-out

    Same protein, different reporting

    “Patients having an AMI can be treated and admitted more quickly, and other patients can be discharged.”

    Peter Kavsak, PhD, Associate Professor of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario, Canada

    Challenges for adoption

    By Diana Smith
    Diana Smith is a writer specializing in medical topics. She is based in Liberty Hill, Texas, USA.

    1. National Association of Clinical Biochemistry (Academy of the American Association for Clinical Chemistry)

      and the International Federation of Clinical Chemists.

    2. European Society of Cardiology and American College of Cardiology.

    3. European Society of Cardiology and American College of Cardiology.

      [1] http://www.who.int/mediacentre/factsheets/fs310/en/

      (date accessed 07/31/2017).

      [2] http://www.who.int/mediacentre/factsheets/fs317/en/

      (date accessed 07/31/2017).

      [3] http://www.bidmc.org/YourHealth/Health-Notes/FirstAid/EmergencyCare/Top5ERvisits.aspx

      (date accessed 07/31/2017).

      [4] Shah ASV, Anand A, Sandoval Y, et al. High-sensitivity cardiac

      troponin I at presentation in patients with suspected acute coronary

      syndrome: a cohort study. Lancet 2015; 386: 2481–8.

      [5] Apple FS, Collinson PO. IFCC Task Force on Clinical Applications

      of Cardiac Biomarkers. Clin Chem. 2012 Jan; 58(1):54-61.

      [6] Eggers KM, et al. European Heart Journal 2016:2417-2424.

      The statements by Siemens’ customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.